Porphyria cutanea tarda (PCT) is one of the inborn porphyrinopathies. It is characterized by abnormal porphyrin synthesis and excretion, cutaneous photodynamic activity, fragility of the skin, and, usually, evidence of liver disease. Schmid, Schwartz, and Watson 1 termed porphyria cutanea tarda and acute intermittent porphyria as hepatic porphyrias, a group of disorders very distinct from congenital (erythropoietic) porphyria. Waldenström2 recognized two forms of porphyria cutanea tarda. One form is familial (PCT hereditaria) and becomes clinically manifest shortly after puberty. It may occasionally be complicated by features of acute porphyria, including the excretion of porphobilinogen in the urine. The other form (PCT symptomatica) becomes manifest later in life and is associated with alcoholism or alcoholic cirrhosis and, in rare instances, with tumors of the liver.
The treatment of porphyria cutanea tarda has been generally disappointing. However, some reports of treatment with dimercaprol (BAL) or edathamil (ethylenediaminetetraacetic acid)3-5 have been
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 7
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.